Algocyte Welcomes Dr Pradip Banerjee as New Board Director

We are pleased to announce that Dr Pradip Banerjee, PhD, MBA, is joining the Board of Directors of Oxford Immune Algorithmics (OIA) | Algocyte following his investment.

Dr Banerjee is an experienced leader with over 25 years across the global life sciences, healthcare, and technology sectors, with a track record of multiple successful company and business exits.

As CEO and Chairman of Xybion Digital, a global SaaS and life sciences technology platform, he has led digital transformation in regulated environments, spanning preclinical study management to quality and compliance systems for global healthcare organisations.

At Accenture, he built and scaled the Life Sciences R&D consulting unit from inception into a major global practice, helping clients align strategy, process, and technology at scale. He also served as President and CEO of the University City Science Center.

Dr Banerjee holds a PhD in Pharmaceutical Sciences from the University of Wisconsin–Madison and an MBA from The Wharton School. He brings deep expertise in strategy, venture building, scaling, and governance to OIA and Algocyte in support of the company’s mission.

Algocyte, created by OIA, is an end-to-end Physical AI platform that enables remote and personalised diagnostic endpoints across multiple healthcare pathways. It integrates subjective data, including symptoms and lifestyle factors, with objective data such as blood and other medical tests to generate diagnostic hypotheses validated through a structured causal pipeline delivering precision and predictive healthcare.